Chagas disease, caused by Trypanosoma cruzi, is a wide spread infection in Latin America. Currently, only 2 partially effective and highly toxic drugs, i.e., benznidazole and nifurtimox, are available for the treatment of this disease and several efforts are underway in the search for better chemotherapeutic agents. Here, we have determined the trypanocidal activity of 2,3-diphenyl-1,4-naphthoquinone (DPNQ), a novel quinone derivative. In vitro, DPNQ was highly cytotoxic at a low, micromolar concentration (LD 50 = 2.5 μM) against epimastigote, cell-derived trypomastigote, and intracellular amastigote forms of T. cruzi, but not against mammalian cells (LD 50 = 130 μM). In vivo studies on the murine model of Chagas disease revealed that DPNQ-treated animals (3 doses of 10 mg/kg/day) showed a significant delay in parasitemia peak and higher (up to 60%) survival rate 70 days postinfection, when compared to control group (infected, untreated). We also observed a 2-fold decrease in the parasitemia between the control group (infected, untreated) and the treated group (infected, treated). No apparent drug toxicity effects were noticed in the control group (uninfected, treated). In addition, we determined that DPNQ is the first competitive inhibitor of T. cruzi lipoamide dehydrogenase (TcLipDH) thus far described. Our results indicate that DPNQ is a promising chemotherapeutic agent against T. cruzi.Chagas disease, or American trypanosomiasis, caused by the protozoan parasite Trypanosoma cruzi, is one of the most deadly infectious diseases in Latin America (Dias et al., 2002). Recent reports suggest that Chagas disease is a potentially emergent public health concern in the United States due to the increased immigration from Latin American countries where the disease is endemic (Leiby et al., 1999(Leiby et al., , 2002Andrade et al., 2004;Diaz, 2007;Kirchhoff and Pearson, 2007;Young et al., 2007). The only commercially available drug, benznidazole, is effective in the acute or early chronic phase of the infection (de Andrade et al., 1996;Andrade et al., 2004), but shows a much decreased performance among infected individuals during the late chronic phase and can cause severe side effects (Urbina and Docampo, 2003). Recently, the emergence of T. cruzi strains resistant to benznidazole has also been reported (Murta and Romanha, 1998). Moreover, thus far, no vaccine is available to prevent or treat Chagas disease (Minoprio, 2001;Martin and Tarleton, 2004;Garg and Bhatia, 2005). These facts clearly emphasize the urgent need of new therapeutic approaches against this parasite.Quinones and their derivatives possess anticancer, antibacterial, antimalarial, and antifungal activities (Kim et al., 2004;Tasdemir et al., 2006;Verma, 2006;Brondani et al., 2007;Ui et al., 2007). Their biological activity is related to the acceptance of 1 and/or 2 electrons to form § To whom correspondence should be addressed.
MATERIALS AND METHODS
Reagents and compoundsDPNQ was synthesized according to the method previously described (Montoya e...